CRNA Share Price Performance
NOK 0.61
-1.28 (-67.57%)
Price NOK 0.61
Share PriceNOK 0.61
CRNA Community Narratives
There are no narratives available yet.
Recent CRNA News & Updates
No updates
Circio Holding ASA Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
Aug 28, 2025
- Earnings per share (EPS)
- 0.55
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -138.7%
Circio Holding ASA Competitors
About CRNA
- Founded
- 2010
- Employees
- 9
- CEO
- WebsiteView website
Circio Holding ASA, a biotechnology company, develops novel circular RNA and immunotherapy medicines. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells. It has a collaboration with Certest Biotec, S.L. for formulation of circVec. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. The company was incorporated in 2010 and is based in Oslo, Norway.
Norwegian Market Performance
- 7 Days: 0.2%
- 3 Months: 6.6%
- 1 Year: 8.7%
- Year to Date: 6.0%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. Meanwhile, the market is actually up 8.7% over the past year. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading